- ChemGenics Pharmaceuticals and Wyeth-Ayerst have entered into an alliance to discover and develop novel therapies for the treatment of bacterial infections. Using ChemGenics gene technologies, the venture aims to identify and prioritize the genes which encode potential molecular targets in bacterial pathogens. Once recognized, the novel drug targets will then be utilized in the development of new antibiotics. ChemGenics stands to receive up to $70 million in research and milestone payments and will also receive royalties on sales of any products arising from the collaboration.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze